Scholarlink

Background <p>Osteopenia is a pre-pathological condition characterized by reduced bone mineral density that may lead to increased fracture risk and to the onset of osteoporosis. Standard treatments for managing osteopenia include supplementation of calcium, vitamin D, and vitamin K. Interestingly, recent studies suggest <span>d</span>-chiro-inositol and α-lactalbumin may enhance bone health through mechanisms such as insulin sensitization and improved nutrient absorption; furthermore, <span>d</span>-chiro-inositol is thought to be a specific mediator of osteoclast activity by inhibiting the expression of several osteoclastogenic genes.</p> Case presentation <p>Six Caucasian patients with osteopenia—four men and two women with an average age of about 41 years—were treated with a daily regimen of calcium (400&#xa0;mg), cholecalciferol (50&#xa0;μg), vitamin K2 (50&#xa0;μg), <span>d</span>-chiro-inositol (150&#xa0;mg), and α-lactalbumin (30&#xa0;mg) for 2&#xa0;months. Even though&#xa0;the results reported no significant changes in T-score&#xa0;value, all patients exhibited improved serum levels of vitamin D and osteocalcin, along with fluctuations in alkaline phosphatase and parathyroid hormone levels.</p> Conclusion <p>Despite the preliminary nature of the obtained data, combined supplementation exerted positive effects on bone metabolism by influencing serum levels of both vitamin D and osteocalcin, thus suggesting enhanced bone formation. Biochemical improvements support the potential of <span>d</span>-chiro-inositol and α-lactalbumin, in addition to traditional supplements, as a therapeutic strategy for managing osteopenia, even though further clinical studies are needed to clarify the effects and related molecular mechanisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in the management of osteopenia: a case series

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月18日

查看全文
  • Maurizio Nordio,
  • Roberto Baldelli

摘要

Background

Osteopenia is a pre-pathological condition characterized by reduced bone mineral density that may lead to increased fracture risk and to the onset of osteoporosis. Standard treatments for managing osteopenia include supplementation of calcium, vitamin D, and vitamin K. Interestingly, recent studies suggest d-chiro-inositol and α-lactalbumin may enhance bone health through mechanisms such as insulin sensitization and improved nutrient absorption; furthermore, d-chiro-inositol is thought to be a specific mediator of osteoclast activity by inhibiting the expression of several osteoclastogenic genes.

Case presentation

Six Caucasian patients with osteopenia—four men and two women with an average age of about 41 years—were treated with a daily regimen of calcium (400 mg), cholecalciferol (50 μg), vitamin K2 (50 μg), d-chiro-inositol (150 mg), and α-lactalbumin (30 mg) for 2 months. Even though the results reported no significant changes in T-score value, all patients exhibited improved serum levels of vitamin D and osteocalcin, along with fluctuations in alkaline phosphatase and parathyroid hormone levels.

Conclusion

Despite the preliminary nature of the obtained data, combined supplementation exerted positive effects on bone metabolism by influencing serum levels of both vitamin D and osteocalcin, thus suggesting enhanced bone formation. Biochemical improvements support the potential of d-chiro-inositol and α-lactalbumin, in addition to traditional supplements, as a therapeutic strategy for managing osteopenia, even though further clinical studies are needed to clarify the effects and related molecular mechanisms.